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INTRODUCTION
In the preceding reports (Monoi, 1995, 1997), we formu-
lated, in terms of molecular mechanics, a new tubular, or
pore-forming, single-stranded helix for all-L polypeptides.
This helix, named the -helix, has a cylindrical pore along
the longitudinal axis of the helix. The inner wall of the pore
is composed of a hydrogen-bonded network of carbonyl and
amino groups of the polypeptide backbone. The diameter of
the pore is 3.7 Å when the closest-approach radii of C and
N atoms are assumed to be 1.45 Å on average. A pore of this
size is sufficient to accommodate small ions and molecules
such as alkali cations and water molecules.
According to conformation-energy calculations (Monoi,
1995, and unpublished data), the -helix is usually unstable;
it is not a preferred configuration for most polypeptide
species. Interestingly, poly-L-glutamine forms a rare excep-
tion; the -helix of this polypeptide is expected to be very
stable. Poly-L-glutamine may hence assume a -helical
structure and behave as an ion channel if it is incorporated
into artificial or biological lipid bilayer membranes.
In the present work, we experimentally inspected the
channel-forming capability of poly-L-glutamine and found
that long-chain poly-L-glutamine can actually produce ion
channels when it is applied to artificial planar lipid bilayer
membranes. The ion channel was cation selective and
showed interesting characteristics. This finding suggests
possible involvement of the cation channel formed by long-
chain poly-L-glutamine in the pathogenesis of the polyglu-
tamine diseases, which comprise Huntington’s disease and
related inherited neurodegenerative disorders that are
caused by the expansion of the CAG trinucleotide repeat
(encoding a polyglutamine stretch) present in each causative
gene.
MATERIALS AND METHODS
Synthesis of poly-L-glutamine
Poly-L-glutamine was synthesized by the continuous-flow FastMoc solid-
phase method on an Applied Biosystems model 433A peptide synthesizer
(Perkin-Elmer Corp., Applied Biosystems Division, Foster, CA). The re-
agents used were as follows: resin, Fmoc-L-Gln(Trt)-Alko resin (Watanabe
Chemical Industries, Hiroshima, Japan); amino acid monomer, Fmoc-L-
Gln(Trt)-OH; coupling reagent, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU); deprotection reagent, pip-
eridine. After 29 or 40 cycles of coupling, the peptide was uncoupled from
the resin and from the trityl protection group by treatment with 95%
aqueous trifluoroacetic acid (TFA). Before the cleavage from the resin, the
terminal amino group of a portion of the 40-cycle peptide sample was
acetylated by acetic anhydride in N-methylpyrrolidone.
In time-of-flight mass spectroscopy (on a Voyager Elite MALDI-TOF
mass spectrometer; PerSeptive Biosystems, Framingham, MA), the 29-
cycle sample showed two definite peaks corresponding to 29- and 28-
residue chains; the 29-residue peak was predominantly higher. The N-
unblocked 40-cycle sample exhibited a series of peaks ranging from 40 to
20 residues, with the highest peak at the 40-residue position. The N-
acetylated 40-cycle sample was partitioned by adding CH2Cl2 to TFA in
which the peptide had been dissolved. The peptide from the lower layer
showed 10 definite peaks corresponding to 40 to 31 residues; the peaks
were highest at the 40-residue position, decreasing rapidly with the de-
crease in the chain length. In what follows, the 40- and the 29-cycle sample
are simply referred to as 40- and 29-residue poly-L-glutamine.
Single-channel measurement in black
lipid membranes
Single-channel experiments were performed at 23  0.5°C. Planar black
lipid membranes were formed across a hole (100–200 m in diameter) in
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a polypropylene septum separating two aqueous electrolyte solutions in a
Teflon chamber. Except for HCl solution, the pH of the chamber solutions
was maintained at 7.0–7.3 with 0.2–5 mM HEPES–Tris buffer. All of the
inorganic salts used had been roasted at 500°C for 24 h. The membrane-
forming solution was asolectin (a mixture of soybean phospholipids)
dissolved in n-decane, 2–3% w/v. Asolectin was purchased from Sigma
Chemical Co. (St. Louis, MO); (asolectin type IV) and Avanti Polar-Lipids
(Alabaster, AL); (soybean phosphatide extract, 20% phosphatidyl choline
content, catalog no. 48-7416-01) and partially purified with acetone and
diethyl ether.
Transmembrane electrical currents were recorded under voltage-clamp
conditions through a patch-clamp amplifier (Nihon Kohden Co., Tokyo,
Japan; model CEZ-2300). The electrodes were Ag–AgCl; no agar salt
bridges were employed to minimize possible contamination. The difference
in the equilibrium electrode potentials, which is prominent in the presence
of asymmetrical Cl concentrations, was compensated for electronically.
Poly-L-glutamine was applied to the chamber solution in the form of dilute
aqueous solution (the final concentration was 5–50 pM), or it was added
directly to the lipid–n-decane solution (usually 0.5–5 pmol/g lipid) in a
glass test tube, sonicated on an ultrasonic cleaner. The two types of
experiments gave the same results.
RESULTS
A brief preliminary consideration—minimum
polypeptide length for transmembrane -helices
Before examining whether poly-L-glutamine can form ion
channels, we estimated, by molecular modeling, the
polypeptide chain length that is sufficient for the -helix to
span the hydrophobic core of usual lipid bilayers. Atomic
coordinate data for the energy-minimized -helix (Monoi,
1995) indicate that a polypeptide chain consisting of 37
residues produces, on the backbone basis, a -helix 30 Å
in length (where the chain length is defined as the distance
along the helical axis between the averaged van der Waals
surface of one helix end and that of the other end). Accord-
ingly, the minimum polypeptide chain length for transmem-
brane -helices will be37 residues. When dimpling of the
bilayer surface occurs at the ends of the helix, the minimum
polypeptide length tends to decrease, possibly by a few
residues at most.
Preparation of poly-L-glutamines of two different
chain lengths
On the basis of the above consideration, we synthesized 40-
and 29-residue poly-L-glutamines to inspect them for the
capability to form ion channels in artificial black lipid
membranes. The method of synthesis employed and the
qualities of the polyglutamines obtained are detailed in the
Materials and Methods section and hence are described here
only briefly.
The synthesis of poly-L-glutamine was performed by the
continuous-flow FastMoc solid-phase method. Care was
taken to maximize coupling yields and minimize side reac-
tions. The terminal amino group of a portion of the 40-
residue polyglutamine sample was acetylated. Time-of-
flight mass spectroscopy showed that the N-unblocked 40-
residue polyglutamine also contains shorter polyglutamine
chains that range in length from 39 to 20 residues, with the
highest mass peak at 40-residue polyglutamine. After being
partitioned between dichloromethane and trifluoroacetic
acid, the N-acetylated 40-residue polyglutamine exhibited
10 definite mass peaks corresponding to 40 to 31 residues,
with the highest peak at 40-residue polyglutamine. This
polyglutamine sample was usually employed for 40-residue
experiments, but the N-unblocked 40-residue polyglutamine
was also used for comparison. The 29-residue polyglu-
tamine sample consisted predominantly of 29-residue
chains.
Detection of single-channel currents; long-lived
open states
When 40-residue poly-L-glutamine was applied to lipid bi-
layer membranes separating two appropriate electrolyte so-
lutions, discrete steplike changes were detected in the trans-
membrane electrical current. The high, or open,
conductance state often lasted for several minutes to tens of
minutes with brief closings that were mostly less than a
second in duration. Occasionally the open state persisted for
more than 1 h. The unit conductance change, or the single-
channel conductance, for 1 molal CsCl was 17  2.4 pS
(average of the upward and downward deflections for 40
different channels  SD) at a membrane potential of 100
mV. This value is for N-acetyl poly-L-glutamine. The N-
unblocked species, however, gave no significantly different
conductance. A typical recording of single-channel current
is shown in Fig. 1, which depicts an initial 18-min trace of
three superposed open states; they lasted for more than 1 h,
being interrupted by closings of varying duration.
Ion selectivity and current-voltage relationship
To examine the cation–anion selectivity of this ion channel,
the zero-current membrane potential, or the reversal poten-
tial, was measured in the presence of concentration gradi-
ents of the same electrolytes across the membrane. It was
50.2  0.2 mV (mixed average of six measurements for
the N-acetyl and N-unblocked 40-residue chains; the value
after the  sign is SEM) at 23°C for 0.1 versus 1.0 molal
solutions of CsCl (the former was placed on the reference
electrode side). This value agrees with the theoretical cat-
ion-induced potential when cations alone are permeable to
the channel. Therefore, the channel is cation selective.
The channel was also permeable to other alkali cations
and H ions. The conductance sequence was H  Cs 
K  Na. The single-channel conductances were 18, 17,
8, and 4 pS, respectively, for 10 mmolal H and 1 molal
alkali cations at a membrane potential of 100 mV (the
anions were Cl throughout).
Fig. 2 shows the dependence of the single-channel current
I on the transmembrane potential V in the presence of 1
molal KCl in both sides of the membrane. The I–V curve is
supralinear, i.e., concave upward in the positive potential
domain and downward in the negative potential domain.
The I–V plot is asymmetrical with respect to the zero-
potential point. The degree of asymmetry is small but
significant.
Channel-forming threshold length of
poly-L-glutamine
The above results are for 40-residue chains. The case was
quite different with 29-residue tracts. To examine the chan-
nel-forming nature of 29-residue poly-L-glutamine, 70 dif-
ferent black membranes were inspected over a total period
of 110 h. The observation time of one black membrane
was usually more than 1 h and did not exceed 2 h. The
membranes were previously doped with poly-L-glutamine,
the concentration of which was 1–5 pmol/g lipid. The mem-
brane potential was maintained at100 mV in the presence
of 1 molal CsCl. Under these conditions, no significant
changes were detected in the transmembrane current. (Un-
der corresponding conditions, the 40-residue poly-L-glu-
tamine produced more than 100 ion channels.) Therefore,
the channel-forming capability of the 29-residue chain, if it
exists at all, is very low compared with that of the 40-
residue chain. The channel-forming threshold length of
poly-L-glutamine is hence between 29 and 40 residues.
DISCUSSION
The polyglutamine diseases
Seven dominantly inherited neurodegenerative disorders are
now known to be caused by the expansion of the CAG
FIGURE 1 A trace of single-channel current in black lipid membrane, induced by poly-L-glutamine in the presence of 1 molal CsCl. The applied
membrane potential is 120 mV. Three superimposed open states are seen; they lasted for more than 1 h, being interrupted by closings of various durations.
The ordinate denotes transmembrane current expressed in pA, and the abscissa, time in minutes. A low-pass filtering at 80 Hz was taken.
FIGURE 2 The I–V plot for the single-channel current I of the cation
channel formed by 40-residue poly-L-glutamine in the presence of 1 molal
KCl on both sides of the black lipid membrane. The plot is supralinear and
asymmetrical with respect to the origin. The points represent averages of
the same three channels. (The membrane-forming lipid solution was pre-
viously doped with poly-L-glutamine, and hence a channel in the mem-
brane is expected to be randomly oriented with respect to the surface
normal direction. Therefore, regardless of the real orientation of the applied
potential V, the orientation of V for each channel is tentatively hypothe-
sized to be such that I in the positive potential domain is greater than I in
the negative potential domain.)
trinucleotide repeat (encoding a polyglutamine stretch)
present in each causative gene: spinobulbar muscular atro-
phy (or Kennedy’s disease) (La Spada et al., 1991), Hun-
tington’s disease (Huntington’s Disease Collaborative Re-
search Group, 1993), spinocerebellar ataxia type 1 (Orr et
al., 1993), dentatorubral-pallidoluysian atrophy (Koide et
al., 1994; Nagafuchi et al., 1994b), Machado-Joseph disease
(or spinocerebellar ataxia type 3) (Kawaguchi et al., 1994),
and spinocerebellar ataxia type 2 (Imbert et al., 1996; San-
pei et al., 1996) and type 7 (David et al., 1997). They are
referred to as the CAG-repeat (or glutamine-repeat) expan-
sion diseases or, simply, the CAG-repeat (or glutamine-
repeat) diseases or the polyCAG (or polyglutamine)
diseases.
In these illnesses, the expanded CAG repeats are located
within the coding regions (La Spada et al., 1991; Hunting-
ton’s Disease Collaborative Research Group, 1993; Orr et
al., 1993; Koide et al., 1994; Nagafuchi et al., 1994b;
Kawaguchi et al., 1994; Imbert et al., 1996; Sanpei et al.,
1996; David et al., 1997) and are translated into the product
proteins (Servadio et al., 1995; Sharp et al., 1995; Trottier et
al., 1995; Yazawa et al., 1995; Ikeda et al., 1996). The
disease genes share no homologous domains except the
CAG repeats (La Spada et al., 1991; Huntington’s Disease
Collaborative Research Group, 1993; Orr et al., 1993;
Koide et al., 1994; Nagafuchi et al., 1994b; Kawaguchi et
al., 1994; Imbert et al., 1996; Sanpei et al., 1996; David et
al., 1997). Accumulated evidence indicates that neuronal
death can be caused by expanded glutamine repeats alone.
How can long-chain polyglutamine be toxic?
One of the several common features shared by the seven
diseases is the existence of a narrow and similar threshold in
the CAG/glutamine repeat length for the onset of the dis-
eases. In normal individuals the repeat length reported is
6–39 glutamines, and in affected individuals, 35–130 glu-
tamines (La Spada et al., 1991; Huntington’s Disease Col-
laborative Research Group, 1993; Orr et al., 1993; Koide et
al., 1994; Nagafuchi et al., 1994b; Kawaguchi et al., 1994;
Imbert et al., 1996; Sanpei et al., 1996; David et al., 1997;
Andrew et al., 1993; Barron et al., 1993; Duyao et al., 1993;
Snell et al., 1993; Stine et al., 1993; Novelletto et al., 1994;
Rubinsztein et al., 1996; Ranum et al., 1994; Komure et al.,
1995). The pathogenetic threshold is hence 35–39 resi-
dues. How can there be such a narrow threshold for the
toxicity of polyglutamine?
Little is known about the molecular mechanism of the
pathogenesis of the polyglutamine diseases. Any patholog-
ical model for the disorders must explain their common
pathological features, which are, besides the problem of the
pathogenetic threshold, 1) the gain-of-function nature of
the mutation, 2) delayed onset and relentless progression
of the disorders, 3) correlation between the repeat length
and the age of onset and between the repeat length and the
severity of the phenotype, 4) cell death specific to neurons
(despite the fact that the disease genes are widely expressed
in nonneuronal cells), and 5) death of specific subsets of
neurons characteristic of each disorder (even though each
disease gene product is expressed in wider areas of the
brain).
Suggestion of a novel pathogenetic hypothesis
for the diseases: the toxic-channel hypothesis
In this work, we have revealed that long-chain poly-L-
glutamine can form characteristic cation channels in vitro.
This finding has led us to suggest a novel pathogenetic
hypothesis for the polyglutamine diseases, as follows. In
cells affected by a polyglutamine disease, causative protein
molecules, which have expanded glutamine repeats, will be
proteolyzed to yield fragments that contain long polyglu-
tamine stretches. If the same channel species as found in
vitro is also produced in vivo from the polyglutamine do-
mains of such fragments, then the cation channel, which has
long-lived open states, will dissipate the potential energies
of permeant cations across subcellular membranes. Espe-
cially in mitochondria, the channel would dissipate the
electrochemical proton gradient and the voltage gradient
across the inner membrane and would reduce ATP produc-
tion. In the course of time, the toxic channel will gradually
accumulate to a critical level, finally to trigger lethal cas-
cade processes leading to cell death. In this toxic-channel
hypothesis, the cation channel formed by poly-L-glutamine
assumes a crucial role.
Recent hypotheses proposed so far about the pathogene-
sis of the polyglutamine diseases focus on the formation of
aggregates (or complexes) of polyglutamine with itself
and/or other intracellular macromolecules. Two major
mechanisms have been offered for the aggregation: hydro-
gen-bond formation involving the amide groups of glu-
tamine side chains (Perutz et al., 1994; Stott et al., 1995)
and covalent bonding catalyzed by transglutaminases
(Green, 1993; Kahlem et al., 1996). Although such aggre-
gate formation generally increases with the expansion of the
glutamine repeats (Cooper et al., 1997; Gentile et al., 1998;
Kahlem et al., 1998), it shows no sharp dependence on the
repeat length. Therefore, the aggregation hypotheses cannot
successfully explain the existence of the narrow pathoge-
netic threshold in the CAG/glutamine repeat length. Within
the framework of the new hypothesis, the aggregation is
secondary or side responses; it might play a part in the fatal
mechanism and/or constitute a cellular protective device to
sequester the toxic polypeptide.
More recently, intranuclear aggregates or inclusions have
often been found in neurons of affected brain regions of
polyglutamine disease patients; those inclusions are immu-
noreactive for antibodies to portions of disease proteins and
to ubiquitin (e.g., DiFiglia et al., 1997; Paulson et al., 1997).
However, evidence now available suggests that the inclu-
sions are not pathogenetic and, instead, may play a role in
the sequestration of the causative protein (see, e.g., Zoghbi
and Orr, 1999, for a review).
Explanation of pathological
features of the diseases
Within the framework of the toxic-channel hypothesis pre-
sented above, the pathogenetic threshold must be approxi-
mately equal to the channel-forming threshold length of
poly-L-glutamine; or, more properly stated, the former
threshold is expected to be longer, more or less, than the
latter because intracellular glutamine repeats will be subject
to enzymic cleavage. The channel-forming threshold length
found above (which was between 29 and 40 residues) agrees
approximately with a range expected from the reported
range (35–39 residues) of the pathogenetic threshold.
Therefore, the hypothesis can explain the existence and
approximate magnitude of the pathogenetic threshold.
Evidently, the toxic-channel hypothesis can also account
for the gain-of-function nature of the mutation and the
delayed onset of the diseases. Taking into account the
intracellular proteolysis of glutamine repeats, it can explain
the correlation between the repeat length and the age of
disease onset and between the repeat length and the severity
of disease symptoms.
In the hypothesis, the toxicity of expanded polyglutamine
is obviously not restricted to nerve cells alone. This is
consistent with the observation (Ikeda et al., 1996) that
apoptosis is induced in nonneuronal cultured COS-7 cells
transfected with cDNA containing expanded CAG repeats.
In the polyglutamine diseases, however, cell death is spe-
cific to neurons despite the fact that the disease genes are
widely expressed in nonneuronal cells (Li et al., 1993;
Strong et al., 1993; Banfi et al., 1994; Nagafuchi et al.,
1994a). This selective vulnerability of nerve cells may be
attributable, at least in part, to their long-lived postmitotic
nature, which will make them susceptible to the accumula-
tion of the toxic channels. Cellular processes specific to
neurons, such as excitotoxicity, may also be responsible for
their vulnerability. The problem of region-specific neuronal
death, however, cannot be explained straightforwardly and
requires further investigation.
Comparison with other ion channels formed by
protein fragments presumed to be
neuropathogenic
So far two different polypeptides that are presumed to be
involved in neurodegenerative diseases have been reported
to form ion channels in lipid bilayer membranes: Alzheimer
amyloid  protein (1–40) (Arispe et al., 1993a,b) and a
peptide fragment (residues 106–126) of the prion protein
(Lin et al., 1997). The former peptide is a proteolytic
product of amyloid precursor protein and is presumed to be
involved in the pathogenesis of Alzheimer’s disease. The
latter was reported to be toxic to cultured neurons (Forloni
et al., 1993; but not confirmed by Kunz et al., 1999).
These two species of ion channels share several perme-
ability characteristics: 1) both are permeable to common
physiological cations; 2) they are also permeable to Cl ion,
with permeability coefficients of 0.1 (amyloid  protein)
and 0.4 (prion fragment) of those for K and Na ion,
respectively; 3) each shows a linear current–voltage rela-
tionship in the presence of symmetrical solutions; and 4)
they have multiple subconductance states (amyloid  pro-
tein) or widely distributed single-channel conductances
(prion fragment), and their single-channel conductances are
large, going up to a few nanosiemens and hundreds of
picosiemens, respectively, at the most.
These characteristics are quite different from those of the
ion channel produced by long-chain poly-L-glutamine in all
of the points raised above, except for the first point.
The -helix as a candidate molecular structure
for the toxic channel
What is the molecular structure of the cation channel
formed by poly-L-glutamine? The observed value for the
channel-forming threshold length of this polypeptide (be-
tween 29 and 40 residues) is difficult to explain in terms of
bundled -helices and -barrel structures. As reported
above (see the section titled A brief preliminary consider-
ation), the minimum polypeptide length for transmembrane
-helices is calculated to be 37 residues or a few residues
less. Therefore, the observed channel-forming threshold can
be accounted for if the channel has a -helical conforma-
tion. We suggest the -helix as a candidate molecular
structure for the novel channel.
As is also stated above (see the Introduction), a molecular
mechanics calculation implies that poly-L-glutamine, as a
rare exception, can form a stable -helix. What is the origin
of this exceptional stability? From the results of a detailed
energy analysis presented previously (Monoi, 1995), this
stability can be ascribed to the presence of a unique con-
formational motif (here named the “amide string”), which is
a string of side-chain amide groups that are serially hydro-
gen-bonded to one another. As illustrated in Fig. 3, each
amide group (CONH2) of the glutaminyl side chains is
hydrogen-bonded to the side-chain amide groups of the
sixth residues before and after it along the primary structure;
thus six strings of side-chain amide groups are formed. The
hydrogen-bond length in the strings is only slightly longer
(by 0.08 Å) than that in the main chain and falls within the
range of standard hydrogen-bond length. The -helical
main chain itself is not stable (Monoi, 1995). In the poly-
glutamine -helix, however, the main chain is stabilized by
six pieces of the amide string motif.
We here add some comments on the degree of hydropho-
bicity of the outer surface of the polyglutamine -helix. In
the -helix, the inner wall of the central pore is composed
of hydrogen-bonded carbonyl and amino groups of the
peptide backbone, and the side chains are situated outside.
As seen in Fig. 3, the outer surface of the polyglutamine
-helix is chiefly occupied by hydrogen-bonded amide
groups and -methylene groups. The amide group is con-
siderably hydrophilic by nature, and hence one might be
doubtful about whether the polyglutamine -helix can be
incorporated effectively into lipid bilayers. However, the
hydrophobicity of the amide group increases when it is
hydrogen-bonded. According to Roseman (1988), the free
energy change of transferring the peptide CAOHON
hydrogen-bonded group from water to CCl4 is 0.6 kcal/
mol, which is much less than the corresponding free energy
change for a non-hydrogen-bonded peptide CONH group
(6.1 kcal/mol). Therefore, it is expected that the outer
surface of the polyglutamine -helix is relatively insensitive
to solvent polarity.
CONCLUDING REMARKS
In this work we have revealed that long-chain poly-L-glu-
tamine forms a characteristic cation channel. The channel is
permeable to monovalent cations, including K, Na, and
H ions, and has a long-lived open state. These character-
istics give the channel a cytotoxic nature. In living cells, the
cation channel would behave as toxic channel by dissipating
the potential energies of the permeant cations across sub-
cellular membranes. Especially in mitochondrial inner
membranes, the channel would dissipate the electrochemi-
cal proton gradient and the voltage gradient and would
reduce ATP production.
For the polyglutamine diseases, there is now a consensus
that neuronal death can be produced by expanded polyglu-
tamine alone. Little is known, however, about the molecular
mechanism of the pathogenesis of the disorders. From the
above considerations, we suggested a novel hypothesis for
FIGURE 3 The -helix of poly-L-glutamine. (Top) Atom species are denoted by a standard coloring: C, green; N, blue; O, red; H, white. (Bottom)
Main-chain atoms are colored red, and side chains green. (Left) Longitudinal view from the N-terminal end of a 73-residue chain; the terminal H atom is
removed. (Right) Lateral view; the N-terminal end is to the left. Atomic radii follow the standard of the CPK molecular models. The -helix has a cylindrical
pore, the diameter of which is 3.7 Å when the closest-approach radii of C and N atoms are assumed to be 1.45 Å on average. In the polyglutamine -helix,
each amide group (CONH2) of the side chains is hydrogen-bonded to the side-chain amide groups of the sixth residues before and after it along the
primary structure; thus strings of side-chain amide groups are formed. The helical conformation is stabilized by six pieces of this conformational motif or
the amide string motif. One of the amide strings is indicated by superimposed chemical symbols in the bottom right figure. A side-chain interamide
hydrogen bond is approximately parallel to the nearest-neighbor main-chain hydrogen bond, and their dipole moments point in opposite directions. This
figure represents the lowest-energy conformation of an infinitely long -helix calculated in terms of molecular mechanics with a modified ECEPP83 force
field (Monoi, 1995).
the pathogenetic mechanism of the disorders. In this hy-
pothesis, the toxic channel formed by glutamine repeats
assumes a crucial role.
Another characteristic of the cation channel is that the
channel-forming threshold length of poly-L-glutamine is
between 29 and 40 residues. The toxic-channel hypothesis
thus provides a straightforward explanation for the exis-
tence and magnitude of the pathogenetic threshold of the
CAG/glutamine repeat length.
Although this study was motivated by the theoretical
prediction that poly-L-glutamine may exceptionally produce
a stable -helix with a tubular shape, the available evidence
for the -helical structure of the novel channel is circum-
stantial at present. Further study is now proceeding on this
point as well as the question of whether the characteristic
cation channel found in vitro is also produced in cells
affected by a polyglutamine disease.
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